Search Results - subject:"Multiple Myeloma"

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database...

Bessou, Antoine; Colin, Xavier; Nascimento, Julie de; … - In: The European journal of health economics 24 (2023) 3, pp. 321-333

Persistent link: https://www.econbiz.de/10014327990

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

Campioni, M.; Agirrezabal, I.; Hájek, Roman; Minarik, J.; … - In: The European journal of health economics : HEPAC ; … 21 (2020) 2, pp. 219-233

Persistent link: https://www.econbiz.de/10012221946

Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany

Basic, Edin; Kappel, Mathias; Misra, Arpit; Sellner, Leopold - In: The European journal of health economics : HEPAC ; … 21 (2020) 9, pp. 1351-1361

Persistent link: https://www.econbiz.de/10012491071

Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from Eortic QLQ Data in Myeloma for Use in Cost effectiveness Analysis

Kharroubi, Samer A; Edlin, Richard; Meads, David; … - Academic Unit of Health Economics, Leeds Institute of … - 2013

Background: Patient Reported Outcome Measures are an important component of the evidence for health technology appraisal. Their incorporation into cost effectiveness analyses (CEA) requires conversion of descriptive information into utilities. This can be done using bespoke utility algorithms....

Persistent link: https://www.econbiz.de/10010701968

Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

Brown, Ruth; Stern, Sean; Dhanasiri, Sujith; Schey, Steve - In: The European Journal of Health Economics 14 (2013) 3, pp. 507-514

LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment. </AbstractSection> Copyright Springer-Verlag 2013

Persistent link: https://www.econbiz.de/10010993909

Principled sure independence screening for Cox models with ultra-high-dimensional covariates

Zhao, Sihai Dave; Li, Yi - In: Journal of Multivariate Analysis 105 (2012) 1, pp. 397-411

consideration is ultra-high. Consider a motivating clinical trial of the drug bortezomib for the treatment of multiple myeloma …

Persistent link: https://www.econbiz.de/10010572279

The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information

Messori, Andrea; Maratea, Dario; Nozzoli, Chiara; Bosi, … - In: PharmacoEconomics 29 (2011) 4, pp. 269-285

Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both …

Persistent link: https://www.econbiz.de/10010614328

Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma

Mühlbacher, Axel; Nübling, Matthias - In: The European Journal of Health Economics 12 (2011) 3, pp. 193-203

Persistent link: https://www.econbiz.de/10009149807

Evaluation of Multiple Models to Distinguish Closely Related Forms of Disease Using DNA Microarray Data: an Application to Multiple Myeloma

Hardin, Johanna; Waddell, Michael; Page, C. David; … - In: Statistical Applications in Genetics and Molecular Biology 3 (2007) 1, pp. 10-10

significance (MGUS) and the overt plasma cell neoplasm multiple myeloma (MM) is quite accurate, yet, for the most part …

Persistent link: https://www.econbiz.de/10005752563

Incremental Cost Analysis of Ambulatory Clinic and Home-Based Intravenous Therapy for Patients with Multiple Myeloma

Coyte, Peter C.; Dobrow, Mark J.; Broadfield, Larry - In: PharmacoEconomics 19 (2001) 8, pp. 845-854

Background: Patients with multiple myeloma and other forms of cancer receiving pamidronate via intravenous (IV … patients with multiple myeloma who attended the Hamilton Regional Cancer Centre for pamidronate therapy from November 1, 1997 … to October 31, 1998 were collected from clinic records. As almost all of these patients with multiple myeloma completed …

Persistent link: https://www.econbiz.de/10005449146